Sister chromatid exchange studies for monitoring DNA damage in lymphocytes of malignant lymphoma patients under cytostatic therapy
| Autor: | Ferlha Erdogan, Mustafa Çengel, All Esat Karakaya, Semra Sardas, Orhan Seyfl ŞardaŞ |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Cyclophosphamide DNA damage Antineoplastic Agents Sister chromatid exchange Gastroenterology Malignant lymphoma Bleomycin Lomustine Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Pharmacology (medical) In patient Lymphocytes Pharmacology business.industry Lymphoma Non-Hodgkin Radiotherapy alone Hodgkin Disease Oncology Doxorubicin business Sister Chromatid Exchange DNA Damage medicine.drug |
| Zdroj: | Anti-Cancer Drugs. 5:487-490 |
| ISSN: | 0959-4973 |
| DOI: | 10.1097/00001813-199408000-00017 |
| Popis: | Sister chromatid exchange (SCE) frequencies were studied in lymphocytes from 45 patients with malignant lymphoma. Fifteen patients were untreated when studied. The mean SCE frequency for these patients was 8.70 +/- 0.99 per mitosis. The mean score for 35 controls was 4.37 +/- 1.19. SCE mean scores were significantly higher in the untreated patients than in the controls (p < 0.001). Nine patients were treated with radiotherapy alone. The mean SCE frequency (6.80 +/- 0.87) they demonstrated was significantly lower (p < 0.01) than that found in untreated patients. Twelve patients received cyclophosphamide 1 month before the study was started. They demonstrated a mean SCE frequency (12.00 +/- 1.31) significantly higher (p < 0.05) than that found in patients who had received regimens that did not contain cyclophosphamide (9.72 +/- 1.32). From these findings we suggest that untreated patients with malignant lymphoma have elevated SCE frequencies, which may be further increased by chemotherapeutic agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|